Presbyopia Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market

Presbyopia Market

DelveInsight’s Presbyopia – Market Insights, Epidemiology, and Market Forecast–2032 report delivers an in-depth understanding of the Presbyopia, historical and forecasted epidemiology as well as the Presbyopia market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The Presbyopia market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Presbyopia market size from 2019 to 2032. The Report also covers current Presbyopia treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Some of the key facts of the Presbyopia Market:

• In the US, the total age-specific cases of Presbyopia were 28,859,295, 33,190,032, 24,012,555, and 15,443,224 for the age group less than 60 years, 60–69 years, 70–79 years, and ≥80 years respectively, in the year 2021. These cases are expected to rise significantly by 2032.
• Among the European countries, Germany had the highest prevalent population of Presbyopia with 36,822,212 cases, followed by Italy with 27,683,651 cases in 2021. On the other hand, Spain had the lowest prevalent population for 2021.
• In 2021, Japan had approximately 34,568,372 total prevalent cases of Presbyopia.

Got queries? Click here to know more about the Presbyopia Market Landscape

Presbyopia Overview

The ability to see things clearly up close. The term “presbyopia” comes from a Greek word that means “old eye.” Most people begin to notice the effect of presbyopia sometime after the age of 40 as the lenses of the eyes naturally lose their elasticity due to the aging process. Presbyopia can be classified according to types incipient presbyopia, functional presbyopia, absolute presbyopia, premature presbyopia, and nocturnal presbyopia. It is mostly due to age-related changes in the proteins within the lens of the eye that cause it to become thicker, harder, and less flexible. 

This loss of flexibility affects the lens’s ability to refract light rays which, in turn, affects the eye’s capacity to focus. Age is the major risk factor for the development of presbyopia along with factors like trauma, systemic disease, cardiovascular disease, or a drug side effect. 

The diagnosis is typically based on the medical history to determine the extent of the vision problem which may show a medication or systemic diseases and disorders that have ocular manifestations. The doctor also tests the vision by having the patient read the text at a typically comfortable distance. Presbyopia cannot be prevented as it is an inevitable part of aging. The goal of treatment is to compensate for the eye’s inability to focus on nearby objects. A variety of options are available for the optical correction of presbyopia. Treatment includes wearing corrective eyeglasses (spectacle lenses) or contact lenses, undergoing refractive surgery, or getting lens implants for presbyopia. Most clinical management of presbyopia includes nonsteroidal anti-inflammatory drugs (NSAIDs), parasympathetic agonists, miotic agents, or some other tempering agents. The commonly used off-label ophthalmic drops have pilocarpine, carbachol, aceclidine, brimonidine, and nepafenac as their main ingredient. They target the ciliary muscles, and change pupil size and elasticity thereby improving near vision. Recently the US FDA approved Vunity developed by AbbVie, for the treatment of presbyopia in adults.

Presbyopia Epidemiology Insights

• According to the American Optometric Association Presbyopia usually becomes visible in the early to mid-40s, but the reduction in the vision of an individual’s focus starts as early as childhood. With the increasing geriatric population and growing digital dependence, the patient pool for Presbyopia is expected to grow in the coming years.
• As per DelveInsight’s estimation, the total prevalent cases of Presbyopia in the 7MM was found to be approximately 289,136,235 cases in 2021. These cases are expected to increase by 2032.
• Among the 7MM, the United States had the highest prevalent cases of Presbyopia with approximately 118,346,762 cases in 2021.
• Assessments as per DelveInsight’s analysts show that in 2021, in the United States, the severity-specific cases of Presbyopia were 20,301,021 and 81,204,086 cases for mild and moderate to severe cases, respectively which are expected to rise significantly by 2032.

Presbyopia Epidemiology Segmentation

• Total Presbyopia prevalent cases
• Total  Presbyopia diagnosed cases.
• Total Presbyopia age-specific cases
• Total Presbyopia severity-specific cases 

Presbyopia Market Outlook 

The pharmacological control of presbyopia is a desirable option for those affected by presbyopia and with an increasing near vision spectacle dependence. Current clinical management of presbyopia in the United States includes off-label treatment using miotic agents, such as pilocarpine and carbachol. One drop of pilocarpine hydrochloride ophthalmic solution 1%, 2%, or 4% (or two drops administered 5 min apart) should be applied topically in the eye(s) for the induction of miosis. Pilocarpine is also being investigated in combination with both other FDA-approved and novel ophthalmic solutions. According to DelveInsight, the overall dynamics of the Presbyopia market are anticipated to change in the coming years owing to the expected launch of emerging therapies.

Learn more by requesting for sample @ Presbyopia Market

Presbyopia Key Companies 

• Eyenovia
• Orasis Pharmaceutical
• Ocuphire Pharma 
• Novartis
• Visus Therapeutics
• And many more

Presbyopia  Therapies

• MicroLine
• CSF-1
• Nyxol 
• UNR844
• VT-101
• And many more

 Market Drivers 

•  Rising prevalence of Presbyopia
•  An upsurge in launch of products
•  Increasing lifestyle changes
•  Increasing research in pharmaceutical treatment
•  Increase in geriatric population

Market Barriers 

• Rising healthcare costs
• Shortage of trained ophthalmologists
• Lack of accessibility of eye care service
• Limitations of Monovision

Table of Contents

•  Key Insights 
•  Report Introduction 
•  Executive Summary of Presbyopia 
•  Disease Background and Overview
•  Epidemiology and patient population
•  The United States 
•  EU 5
•  Presbyopia Emerging Therapies
•  Presbyopia Market Outlook
•  Market Access and Reimbursement of Therapies
•  Market Drivers 
•  Market Barriers 
•  Appendix
•  Presbyopia Report Methodology
•  DelveInsight Capabilities
•  Disclaimer

Click here to read more about Presbyopia Market trends

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Adya Kaul
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/